Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

Fulvestrant in Advanced Male Breast Cancer

By Agrawal Amit   Cheung Kwok-Leung   Robertson John FR  

Breast Cancer Research and Treatment, Vol. 101, Iss. 1, 2007-01 ,pp. : 123-123

Springer Publishing Company

Access to resources Recommend Favorite

Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Aminoglutethimide: a Phase II Multicentre Multinational Study

By Exemestane Study Group   Thurlimann B.   Paridaens R.   Serin D.   Bonneterre J.   Roche H.   Murray R.   di Salle E.   Lanzalone S.   Zurlo M.G.   Piscitelli G.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1767-1773

Elsevier

Access to resources Recommend Favorite

Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 137-138

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression Following Antiestrogen Therapy

By Kate McKeage   Monique P. Curran   Greg L. Plosker  

American Journal of Cancer, Vol. 3, Iss. 4, 2004-01 ,pp. : 267-270

Adis International

Access to resources Recommend Favorite